Vanguard Group Inc. Cuts Stock Position in Hims & Hers Health, Inc. $HIMS

Vanguard Group Inc. trimmed its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 8.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,478,744 shares of the company's stock after selling 1,778,372 shares during the quarter. Vanguard Group Inc. owned 8.32% of Hims & Hers Health worth $546,047,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of HIMS. UMB Bank n.a. grew its position in shares of Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after buying an additional 933 shares during the period. Larson Financial Group LLC increased its position in Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock worth $42,000 after buying an additional 458 shares in the last quarter. Fifth Third Bancorp increased its stake in shares of Hims & Hers Health by 165.4% in the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock worth $46,000 after purchasing an additional 961 shares in the last quarter. Tsfg LLC purchased a new stake in shares of Hims & Hers Health during the first quarter worth about $46,000. Finally, N.E.W. Advisory Services LLC bought a new stake in Hims & Hers Health in the 1st quarter valued at $49,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Down 1.4%

Shares of NYSE HIMS traded down $0.63 during trading hours on Monday, hitting $45.40. 9,708,744 shares of the stock were exchanged, compared to its average volume of 33,854,742. The firm has a fifty day moving average price of $52.96 and a 200-day moving average price of $45.72. The company has a market cap of $10.26 billion, a PE ratio of 56.83, a PEG ratio of 2.91 and a beta of 2.08. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm's revenue was up 72.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.06 earnings per share. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity

In other news, insider Patrick Harrison Carroll sold 60,000 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the sale, the insider owned 169,940 shares of the company's stock, valued at $9,105,385.20. This represents a 26.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of Hims & Hers Health stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the sale, the chief executive officer owned 2,214,769 shares of the company's stock, valued at approximately $112,023,016.02. This represents a 22.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,273,034 shares of company stock worth $66,425,573 over the last three months. Corporate insiders own 17.71% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on HIMS. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a report on Monday, June 23rd. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Finally, Piper Sandler restated a "neutral" rating and set a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.